![](/img/cover-not-exists.png)
Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Gibbs, John P., Doshi, Sameer, Kuchimanchi, Mita, Grover, Anita, Emery, Maurice G., Dodds, Michael G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Blom, DirkLanguage:
english
Journal:
The Journal of Clinical Pharmacology
DOI:
10.1002/jcph.840
Date:
November, 2016
File:
PDF, 941 KB
english, 2016